Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03911557
Title Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors John L. Villano, MD, PhD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Markey Cancer Center Lexington Kentucky 40536 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field